DOCSLIB.ORG

The Jordan Report: Accelerated Development of Vaccines 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Jordan Report: Accelerated Development of Vaccines 2007 THE JORDAN REPORT ACCELERATED DEVELOPMENT OF VACCINES 2007 U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases NIH Publication No. 06-6057 May 2007 www.niaid.nih.gov Images on cover, clockwise from top: © The World Bank; Courtesy of the National Library of Medicine; istock.com; Courtesy of the National Library of Medicine Table of Contents INTRODUCTION VACCINE UPDATES Introduction by Carole Heilman, Ph.D. .....................................3 Supporting the Nation’s Biodefense .........................................69 Animal Models for Emerging Infectious Diseases Tribute to Maurice R. Hilleman, Ph.D., and John R. La Montagne, Ph.D., by William S. Jordan, Jr., M.D. .....................5 Hepatitis C..................................................................................75 HIV/AIDS ...................................................................................77 EXPERT ARTICLES Dale and Betty Bumpers Vaccine Research Center The Immunology of Influenza Infection: Implications Human Papillomavirus (HPV) .................................................87 for Vaccine Development Cancer Vaccine Development at NCI Kanta Subbarao, M.D., M.P.H., Brian R. Murphy, M.D., Influenza .....................................................................................89 and Anthony S. Fauci, M.D........................................................11 Malaria ........................................................................................95 Vaccine Production and Supply: Vulnerabilities in the Present System Severe Acute Respiratory Syndrome (SARS)..........................103 Walter A. Orenstein, M.D., Alan R. Hinman, M.D., Streptococcus Pneumoniae......................................................109 M.P.H., Lance E. Rodewald, M.D. .............................................21 The Gambia Pneumococcal Vaccine Trial Project BioShield: A Tool for Developing, Using, and Tuberculosis..............................................................................113 Stockpiling Needed Public Health Emergency Medical Countermeasures Varicella-Zoster Virus...............................................................119 Noreen A Hynes, M.D., M.P.H. .................................................27 West Nile Virus.........................................................................123 Using Genomics to Identify Novel Vaccine Candidates Against Pathogens APPENDIXES Hervé Tettelin, Ph.D., Rino Rappuoli, Ph.D., and Claire M. Fraser-Liggett, Ph.D...................................................37 Appendix A: Status of Vaccine Research and Development .....................................................................127 Adolescent Immunizations: Will the Shots Hit Their Targets? Amy B. Middleman, M.D., M.P.H., M.S.Ed..............................43 Appendix B: Vaccines Licensed for Immunization and Distribution in the United States ............................................141 Phase IIB/Test of Concept Trials for HIV Vaccine Efficacy Evaluation Appendix C: HIV Vaccine Candidates in Preclinical Susan P. Buchbinder, M.D. ........................................................53 Development ............................................................................145 The Animal Rule from a Vaccine Development Perspective Appendix D: Clinical Trials of HIV Vaccine Candidates in Mark J. Abdy, D.V.M., Ph.D., Michael Merchlinsky, Ph.D., and HIV-Uninfected Adults............................................................147 Drusilla L. Burns, Ph.D. .............................................................61 Appendix E: Recommended U.S. Childhood Immunization Schedule...........................................................151 Appendix F: Recommended U.S. Adult Immunization Schedule ....................................................................................155 THE JORDAN REPORT 2007 1 2 THE JORDAN REPORT 2007 Introduction Carole Heilman, Ph.D. binant DNA. Scientists also continue to additional benefit of the vaccine may be improve existing vaccines and identify to decrease transmission of B. pertussis new vaccine candidates to prevent diseases to infants, who are particularly vulnerable Background for which no vaccines currently exist. By to severe illness from B. pertussis.The t has been almost 25 years since the increasing their understanding of the illness affects 50 million people world­ first vaccine research and development immune system and how it fights off wide each year. I“state of the science” report, otherwise harmful microbes, researchers have also known as The Jordan Report, was pub­ made exciting developments in vaccine Challenges and Opportunities lished by the National Institute of Allergy research methodology, which have Despite considerable progress in vaccinol­ and Infectious Diseases (NIAID), part of resulted in recent clinical trials to evaluate ogy, the emergence of new infectious the National Institutes of Health. Since candidate vaccines against malaria, diseases, the re-emergence of old diseases, that time, significant scientific progress tuberculosis and West Nile virus. and the persistence of intractable diseases has been made in developing new and An exciting scientific milestone (sometimes due to drug resistance), better vaccines against a wide array of occurred in January 2004, when a new make infectious diseases some of the infectious diseases, including those that tuberculosis vaccine entered Phase I most complex and difficult challenges are emerging or re-emerging. clinical trials. NIAID has supported facing the public health community today. Historically, vaccines have led to some research on this candidate vaccine since HIV/AIDS, malaria, and tuberculosis of the greatest public health triumphs ever, its earliest stages. The vaccine was the are still among the leading killers world­ including the eradication of naturally- first to reach human trials in the United wide and no licensed vaccines against occurring smallpox from the globe more States and, in fact, the first new tubercu­ them currently exist. In addition, new than 50 years ago, and the near-eradication losis vaccine to be tested in more than infectious diseases continue to emerge. of polio. In addition, there has been a 60 years. Since the last edition of The Jordan significant reduction in the disease burden Childhood and adolescent vaccines Report, the world has seen an outbreak imposed by measles, mumps, hepatitis, are another area in which significant of a novel coronavirus termed “severe influenza, diphtheria, and many other advances have been made. In March acute respiratory syndrome” (SARS), infections. 2005, global health leaders presented new yearly West Nile virus outbreaks, and This edition of the Jordan Report research findings showing that vaccinating most recently, the continuing threat of a outlines a number of significant advances infants against Streptococcus pneumoniae— potential avian influenza pandemic. made in infectious disease vaccine a bacterium that causes deadly pneumonia, Even as infectious diseases emerge research and development since the last meningitis, and sepsis—could substan­ and re-emerge, however, scientists con­ document was published in 2002. In tially reduce death and serious illness tinue to rapidly develop and design addition, it offers a variety of perspectives among children in the developing world. novel vaccine approaches. These include from experts in the field on timely This study, The Gambia Pneumococcal developing new adjuvants and novel immunization topics, including adolescent Vaccine Trial, was supported in part by delivery systems such as oral, nasal, vaccine platforms and vaccine supply. the NIAID. transcutaneous vaccinations, and com­ In October 2005, study results were bination vaccine strategies. In addition, Advances in Vaccine Research released for the NIAID-supported acellular the application of genomic and post- and Development pertussis trial, which showed that the genomic technologies in the development One factor contributing to the rapid candidate vaccine was more than 90 of a new generation of tailor-made expansion of the current vaccine arsenal percent effective in preventing the trans­ vaccines has the potential to provide a is the acceleration of technological mission of B. pertussis in people between stunning opportunity to “customize” advances, including those using recom­ the ages of 15 and 65. An important vaccines against novel microbes. INTRODUCTION 3 There is also great enthusiasm and renewed effort for exploring opportunities for vaccine development in less traditional areas. These areas include therapeutic vaccines for managing chronic diseases, vaccines for controlling autoimmune dis­ eases, and vaccines against diseases of particular public health concern that have implications for global health. Positive Spin-offs of Basic Research NIAID’s investment in research on biode­ fense pathogens will have many positive implications for global public health. Studies of microbial biology and the pathogenesis of organisms with bioterror potential will lead to a better under­ standing of other, more common and naturally occurring infectious diseases and advance future vaccine development pathways and strategies. Furthermore, this research promises to enhance the understanding of molecular and cellular mechanisms (including regulation) of the immune system, which may help in the search for new ways to treat and prevent a variety of immune-mediated diseases
Load more

Recommended publications
  • The Bill & Melinda Gates Foundation Tax Return Was E-Filed with The
    The Bill & Melinda Gates Foundation tax return was e-filed with the Internal Revenue Service. The tax return and accompanying attachments posted on our website are presented as a view of the electronically filed data. Please note for ease of navigating the tax return we have bookmarked the various sections of the return. efile GRAPHIC print - DO NOT PROCESS ORIGINAL DATA - EIN: 562618866 Return of Private Foundation OMB No. 1545-0052 Form 990-PF or Section 4947(a)(1) Nonexempt Charitable Trust Treated as a Private Foundation 2007 Department of the Treasury Note: The foundation may be able to use a copy of this return to satisfy state reporting requirements. Internal Revenue Service For calendar year 2007 , or tax year beginning 01-01-2007 and ending 12-31-2007 G Check all that apply: Initial return Final return Amended return Address change Name change Name of foundation A Employer identification number Use the IRS BILL & MELINDA GATES FOUNDATION label. 56-2618866 Otherwise, B Telephone number (see page 10 of the instructions) print Number and street (or P.O. box number if mail is not delivered to street address) Room/ suite or type. 1551 EASTLAKE AVENUE EAST (206) 709-3100 See Specific Instructions. City or town, state, and ZIP code C If exemption application is pending, check here SEATTLE, WA 98102 D 1. Foreign organizations, check here . H Check type of organization: Section 501(c)(3) exempt private foundation 2. Foreign organizations meeting the 85% test, check here and attach computation Section 4947(a)(1) nonexempt charitable trust Other taxable private foundation E If private foundation status was terminated I Fair market value of all assets at end J Accounting method: Cash Accrual under section 507(b)(1)(A), check here of year (from Part II, col.
    [Show full text]
  • Developing Vaccines for Neglected Diseases
    Developing Vaccines for Neglected Diseases Vaccine Technologies II Albufeira, Portugal June 5th, 2008 Douglas Holtzman, Ph.D., M.P.H. Senior Program Officer, Global Health Program Bill & Melinda Gates Foundation 1 Three Programs, One Goal: Equity US Program » High school education » Public library internet access Global Development » Financial services for the poor (e.g. microfinance) » Agricultural productivity and markets Global Health 2 Perspective on Global Health The vision: To ensure that a child born in the developing world has the same chance for good health as a child born in the developed world The goal: Build on advances in science and technology to save lives, improve health, and reduce disease in the developing world 3 Prioritization Burden of disease Inequity of burden Lack of attention Possibility for impact 4 Disease Areas HIV (vaccines, microbicides, treatment, prevention, education) TB (drugs, vaccines, diagnostics) Malaria (drugs, vaccines, vector control, diagnostics, scale-up) Pneumonia Diarrhea Nutrition Maternal Health Discover, develop and deliver Kinetoplastids innovative solutions Helminths HPV Dengue/Japanese Encephalitis Polio 5 Partnerships Global Alliance for Vaccines and Immunization (GAVI) Global Fund for AIDS, TB and Malaria HIV Vaccine Enterprise Medicines for Malaria Venture (MMV) Malaria Vaccine Initiative (MVI) MACEPA PATH Vaccine Solutions (PVS) Aeras (TB Vaccines) Global Alliance for TB Drug Development (GATB) ACHAP Grand Challenges in Global Health IVI/PDVI Etc….
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • 2004 Albert B. Sabin Gold Medal Address Delivered by Award Recipient William S
    2004 Albert B. Sabin Gold Medal Address Delivered by Award Recipient William S. Jordan, Jr., M.D. With a Tribute by John R. LaMontagne, Ph.D. May 25, 2004 Arlington, Virginia INTRODUCTION by H.R. Shepherd, D.Sc. Chairman, The Albert B. Sabin Vaccine Institute he Sabin Vaccine Institute pursues Dr. Albert B. Sabin’s vision of a T world protected from disease by vaccines. The annual awarding of the Sabin Gold Medal has always been among our most meaningful traditions. The 2004 award was presented in May to an icon in vaccine research, William S. Jordan, Jr., M.D., at a ceremony in Arlington, Virginia, during the 7th Annual Conference on Vaccine Research, co-organized by the Sabin Vaccine Institute. The positive impact of vaccines on the health and well being of humanity continues to be a marvel of our modern world. Vaccine improvements, new vaccines, and vaccines in the pipeline represent an advancing field of science that brings untold preventive benefit to millions around the world. Along with his career in vaccine research, Dr. Jordan has engaged in compiling the record of scientific advancements in the field. His name is synonymous with both vaccine research and the compendium—The Jordan Report—that for 25 years has been a repository for advances in the vaccine field. The Sabin Gold Medal Advisory Committee, chaired by Maj. Gen. Philip K. Russell, M.D. (USA Ret.), selected Dr. Jordan for this honor after canvassing 300 members of the scientific community. We are pleased to recognize Dr. Jordan with this honor, noting his exemplary contributions in the vaccine field and commitment to lifesaving medical discoveries.
    [Show full text]
  • IN the MOUNTIES WE TRUST: a Study of Royal Canadian Mounted
    IN THE MOUNTIES WE TRUST: A Study of Royal Canadian Mounted Police Accountability by STEPHEN LORENZ WETTLAUFER A thesis submitted to the Department of Sociology in conformity with the requirements for the degree of Master of Arts Queen’s University Kingston, Ontario, Canada July, 2011 Copyright © Stephen Lorenz Wettlaufer, 2011 Abstract Police and Canadian citizens often clash during protests sometimes resulting in violent outcomes. Due to the nature of those altercations, there are few other events that require oversight more than the way police clash with protesters and there is a history of such oversight resulting in a number of Federal Parliamentary documents, Parliamentary Committee reports Task Force reports, reports arising from Public Interest Hearings of the Commission for Complaints Against the RCMP, and testimony at various hearings and inquiries which have produced particular argumentative discourses. Argumentative discourses that have a great effect on the construction of a civilian oversight agency of the RCMP is the focus of this thesis. This thesis examines how it is that different discourses, as represented by argumentative themes in these reports, intersect with one another in the process of creating a system of accountability for the RCMP. Through the lens of complaints that arise from protest and police clashes one may conclude that the current system of accountability does not adhere to a practice of protecting the most fundamental rights as prescribed by the Canadian Charter of Rights and Freedoms; nor would the currently proposed legislation contained within Bill C‐38 alter the system in a substantial way to allow for such protections. The power dynamic between the Commissioner of the Force and the Commission for Complaints Against the RCMP favours the police force in the current and proposed system.
    [Show full text]
  • Robert Purcell: Okay
    Office of NIH History Oral History Interview with Dr. Robert H. Purcell (NIAID, LID) Conducted on December 7, 2005, by Dr. Lisa K. Walker At the National Institutes of Health, Bethesda, Maryland Abstract: Dr. Purcell describes his education and training, his early career in the Laboratory of Infectious Diseases, and his work since he has headed LID studies of hepatitis viruses. He describes how the LID broadened its work, from a focus on viruses causing respiratory diseases through the early 1960s, to include hepatitis as well as gastroenteritis viruses. He also discusses internal collaborations at NIH and extramural collaborations, and many of the chance findings and coincidences that helped to further study of hepatitis and control of infection. Dr. Purcell also comments on how advances in technology and instrumentation have influenced the study of hepatitis viruses. Lisa Walker: I would like to start out by hearing a little bit about your growing up, and your family and your decisions as you entered university and training in chemistry to begin with. Robert Purcell: Okay. I was born in Iowa and moved to Texas when I was six months old, and spent my first nine years in Dallas, Texas. Then my family moved to rural Oklahoma, and that’s where I lived until I finished college and then went off to medical school. I guess I developed an interest in science from my brother, who was in college and was taking science courses, [and] who would come home with interesting little tidbits about things, and that really kind of excited me. The school I went to, since it was in rural Oklahoma, actually was a minimal school.
    [Show full text]
  • COLLEGE of LETTERS and SCIENCE ALUMNI: KNOWLEDGE in ACTION COLLEGE of LETTERS and SCIENCE Dear Friends and Colleagues, Dean, Nicol C
    THE COLLEGE OF LETTERS AND SCIENCE • MONTANA STATE UNIVERSITY • 2016-2017 • VOLUME 13 COLLEGE OF LETTERS AND SCIENCE ALUMNI: KNOWLEDGE IN ACTION COLLEGE OF LETTERS AND SCIENCE Dear friends and colleagues, Dean, Nicol C. Rae Associate Dean, David Cherry In 2016, Montana State University Associate Dean, Bridget Kevane celebrated and honored the legacy of Director of Finance and Administration, Mindy Brown Assistant to the Dean, Sarah Miller Maurice Hilleman, the College of Letters Administrative and Student Support Coordinator, and Science’s—and arguably MSU’s— Nicol Rae. Jennifer Storment most world-changing alumnus. Communications Director, Jody Sanford Advising Coordinator, Erica Dungan Hillman graduated from MSU in 1941 with degrees in chemistry and Accounting Operations Manager, Cassandra Balent microbiology. He pursued a career as a microbiologist, specializing in vaccinology Information Technology Director, Michael Wright and developing over 40 vaccines, an unparalleled record of productivity. Of the COLLEGE OF LETTERS AND SCIENCE 14 vaccines routinely recommended in current vaccine schedules, he developed ADVISORY COUNCIL eight: those for measles, mumps, hepatitis A, hepatitis B, chickenpox, meningitis, Michael Beehler Betsy Quammen pneumonia and Haemophilus influenzae bacteria. He also played a role in the Julianne Bye Peter Roos discovery of the cold-producing adenoviruses, the hepatitis viruses and the cancer- Ingrid Degreef Peter Sadowski Marshall Gingery Bradley Snow causing virus SV40. He is credited with saving more lives than any other medical Ariana Paliobagis Gary Stoner scientist of the 20th century. Gary Popiel William Yellowtail Jr. In April of this year, MSU held the Maurice Hilleman Vaccine Symposium, DEPARTMENTS AND DEPARTMENT HEADS featuring some of the nation’s most noted experts in vaccine.
    [Show full text]
  • VIP Visits DIPLOMATIC BLUEBOOK 2006
    VIP Visits DIPLOMATIC BLUEBOOK 2006 VIP Visits January 1, 2005-December 31, 2005 <VIP Visits covered in this table and notes> 1. The period covered in this table is from January 1, 2005 to December 31, 2005. 2. Regarding visits by Japanese VIPs, the visits to other countries have been listed for the Imperial Family, the Prime Minister, Special Envoys of the Prime Minister, Cabinet Ministers, Senior-Vice Ministers for Foreign Affairs, Parliamentary Secretaries for Foreign Affairs, the Speaker of the House of Representatives, and the President of the House of Councillors. 3. Regarding visits by VIPs from other countries and institutions, this list principally includes VIPs of or above the rank of foreign minister in each country as well as the heads of each international organization who 1) either met with Japanese VIPs of or above the rank of Minister for Foreign Affairs or 2) had the purpose of attending international conferences held in Japan. 4. Meetings that were held with VIPs from third-party countries on occasions when Japanese VIPs attended international conferences are listed in the column “Purpose of visit and main schedule” of the visits to the host country of the conference. 5. The titles of VIPs are those held at the time when the visits were made. 6. The period refers to the duration of stay in the country or region that VIPs were visiting. Name of country or region Name of VIP Period Purpose of visit and main schedule (1) Asia and the Pacific Australia ToSenior Vice-Foreign Minister 2/10-2/13 Attendance at the Third Australia-Japan
    [Show full text]
  • Fire Departments of Pathology and Genetics, Stanford University School of Medicine, 300 Pasteur Drive, Room L235, Stanford, CA 94305-5324, USA
    GENE SILENCING BY DOUBLE STRANDED RNA Nobel Lecture, December 8, 2006 by Andrew Z. Fire Departments of Pathology and Genetics, Stanford University School of Medicine, 300 Pasteur Drive, Room L235, Stanford, CA 94305-5324, USA. I would like to thank the Nobel Assembly of the Karolinska Institutet for the opportunity to describe some recent work on RNA-triggered gene silencing. First a few disclaimers, however. Telling the full story of gene silencing would be a mammoth enterprise that would take me many years to write and would take you well into the night to read. So we’ll need to abbreviate the story more than a little. Second (and as you will see) we are only in the dawn of our knowledge; so consider the following to be primer... the best we could do as of December 8th, 2006. And third, please understand that the story that I am telling represents the work of several generations of biologists, chemists, and many shades in between. I’m pleased and proud that work from my labo- ratory has contributed to the field, and that this has led to my being chosen as one of the messengers to relay the story in this forum. At the same time, I hope that there will be no confusion of equating our modest contributions with those of the much grander RNAi enterprise. DOUBLE STRANDED RNA AS A BIOLOGICAL ALARM SIGNAL These disclaimers in hand, the story can now start with a biography of the first main character. Double stranded RNA is probably as old (or almost as old) as life on earth.
    [Show full text]
  • B Efforts Aimed at Realizing Prosperity in the International Community
    CHAPTER 3 JAPAN’S FOREIGN POLICY IN MAJOR DIPLOMATIC FIELDS BEfforts Aimed at Realizing Prosperity in the International Community Asia-Pacific Economic Cooperation (APEC) and the Overview Asia-Europe Meeting (ASEM), and of multilayered eco- The global economy in 2004 generally made a steady re- nomic relations, including those between Japan and the covery, despite instability caused by rising crude oil United States (US) as well as Japan and Europe. The prices and some other factors. fourth is strengthening economic security, including in Under these circumstances, Japan has promoted the areas of energy, food, marine issues, piracy, and fish- economic foreign policy focusing on the following five eries (including whaling). The final one is support for issues as its priorities, with the objective of further Japanese companies overseas and the promotion of in- strengthening the economies of both Japan and the vestments to Japan. world. The first is maintaining and strengthening the Moreover, while the international community ac- multilateral trading system (global efforts) and promot- knowledges the importance of science and technology ing economic partnership at the regional and bilateral to resolve various global issues, Japan has been advanc- levels to complement the multilateral trading system. ing bilateral and multilateral cooperation, using its ex- The second is active participation in international efforts perience as the world leader in science and technology. on globalization aimed at coping effectively with global While Japan has been making efforts to enhance its issues, such as working on world economic growth and own economic interests, it also endeavors to respond ef- sustainable development. The third is strengthening fectively to these various issues in pursuit of the pros- frameworks for interregional cooperation such as the perity of the international community.
    [Show full text]
  • HIV/AIDS Technologies: a Review of Progress to Date and Current Prospects
    Working Paper No.6 HIV/AIDS Technologies: A review of progress to date and current prospects COMMISSIONED BY: aids2031 Science and Technology Working Group AUTHORED BY: KEITH ALCORN NAM Publications Disclaimer: The views expressed in this paper are those of the author(s) and do not necessarily reflect the official policy, position, or opinions of the wider aids2031 initiative or partner organizations aids2031 Science and Technology working group A review of progress to date and current prospects October 2008 Acronyms 3TC lamivudine ANRS Agènce Nationale de Récherche sur la Sida ART Antiretroviral therapy ARV Antiretroviral AZT azidothymidine or zidovudine bDNA branched DNA CDC US Centers for Disease Control CHER Children with HIV Early Antiretroviral therapy (study) CTL Cytotoxic T-lymphocyte D4T stavudine DSMB Data and Safety Monitoring Board EFV Efavirenz ELISA Enzyme Linked Immunosorbent Assay FDC Fixed-dose combination FTC Emtricitabine HAART Highly Active Antiretroviral Therapy HBAC Home-based AIDS care HCV Hepatitis C virus HPTN HIV Prevention Trials Network HSV-2 Herpes simplex virus type 2 IAVI International AIDS Vaccine Initiative IL-2 Interleukin-2 LED Light-emitting diode LPV/r Lopinavir/ritonavir MIRA Methods for Improving Reproductive Health in Africa trial MSF Médecins sans Frontières MSM Men who have sex with men MVA Modified vaccinia Ankara NIH US National Institutes of Health NRTI Nucleoside reverse transcriptase inhibitor NNRTI Non-nucleoside reverse transcriptase inhibitor OBT Optimised background therapy PCR Polymerase
    [Show full text]
  • View Annual Report
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission file number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9 Innovation Way, Suite 100, Newark, DE 19711 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (302) 355-0650 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered Common Stock, $0.001 par value NYSE MKT Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]